SCHEMBL2473736

SCHEMBL2473736

c1ccc2sc(B3OB(c4cc5ccccc5s4)OB(c4cc5ccccc5s4)O3)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.47
ASIC3 Q9UHC3 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.47
AGXT P21549 1/20 0.43
ADRB2 P07550 1/20 0.43
MGLL Q99685 1/20 0.42
BCL2L1 Q07817 1/20 0.41
CA2 P00918 2/20 0.40
APP P05067 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119228 0.80 LPL (0.44) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL2988147 0.80 CYP2A6 (0.41) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL9173482 0.71 CYP1A2 (0.33) CYP2A6
SCHEMBL15581069 0.70 LPL (0.45)
SCHEMBL329714 0.69 CA2 (0.50) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL2451527 0.68 CYP2A6 (0.64) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL29732980 0.67 APP (0.63) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL845603 0.67 APP (0.63) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL4961407 0.67 CYP2A6 (0.69) CYP2A6ASIC3LOXL2AGXTADRB2
SCHEMBL2150464 0.67 APP (0.57) CYP2A6ASIC3LOXL2AGXTADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 CYP2A6 1821/4885ASIC3 3383/4885LOXL2 3220/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 CYP2A6 1821/4885ASIC3 3383/4885LOXL2 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.